BUGUNGI KUNDA SURUNKALI YURAK YETISHMOVCHILIGI: ADABIYOTLAR TAHLILI
##article.subject##:
surunkali yurak yetishmovchiligi, qon otib berish fraksiyasi, patogenezi, davolash, tashxislash, SGLT2, AAFI, o‘lim.##article.abstract##
Maqolada chap qorincha otish fraksiyasiga ko’ra (HFrEF, HFmrEF, HFpEF) va NYHA bo’yicha funksional sinflarga asoslangan surunkali yurak yetishmovchiligining zamonaviy tasnifiga e’tibor qaratilgan. Tashxis qo‘yishning zamonaviy yondashuvlari, xususan biomarkerlar va tasvirlash usullaridan foydalanish masalalari yoritib berilgan. Zamonaviy dori-darmon bilan davolash strategiyalari, jumladan RAAS ingibitorlari, beta-blokatorlar, aldosteron antagonistlari va SGLT2 ingibitorlarini qo‘llash batafsil ko‘rib chiqilgan. Bu usullar chuqur tahlil qilingan. Bundan tashqari, davolashning yangi yo‘nalishlari va besh yillik o‘lim ko‘rsatkichlari haqidagi ma’lumotlar ham taqdim etilgan. Maqolada surunkali yurak yetishmovchiligining epidemiologik va klinik jihatlarini aks ettiruvchi jadvallar va diagrammalar mavjud. Ushbu sharh ko‘p tarmoqli yondashuvning zarurligi va shaxsga yo‘naltirilgan davolash sohasida yanada chuqur tadqiqotlar o‘tkazish kerakligini ta’kidlaydi.
Библиографические ссылки
Armstrong P.W. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. NEJM. 2022.
Bozkurt B. et al. Universal Definition and Classification of Heart Failure. JACC. 2021.
Gheorghiade M. et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013.
Komajda M. et al. Heart failure with preserved ejection fraction: a multifactorial syndrome. Eur Heart J. 2016.
McDonagh T.A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021.
Metra M. & Teerlink J.R. Heart failure. Lancet. 2017.
Packer M. et al. Effect of empagliflozin in patients with heart failure. NEJM. 2021.
Pitt B. et al. The role of mineralocorticoid receptor antagonists in cardiovascular disease. Eur Heart J. 2018.
Ponikowski P. et al. Heart failure: preventing disease and death worldwide. ESC White Paper. 2020.
Savarese G. & Lund L.H. Global public health burden of heart failure. Card Fail Rev. 2017.
Swedberg K. et al. Guidelines on diagnosis and treatment of CHF. Eur Heart J. 2005.
Vaduganathan M. et al. Sodium-glucose co-transporter 2 inhibitors in heart failure: State of the art. Eur Heart J. 2020.
Yancy C.W. et al. 2017 ACC/AHA/HFSA Guideline Update for the Management of Heart Failure. Circulation. 2017.
